Purdue Pharma Hit with $5.5B Penalty as Opioid Settlement Clears Key Hurdle

Purdue Pharma, the maker of OxyContin, has been sentenced to $5.5 billion in fines and penalties following its 2020 guilty plea to charges of misleading government regulators and paying kickbacks to doctors to boost opioid sales.

The sentencing in a New Jersey federal court clears the way for the company to be dissolved through bankruptcy, with its assets directed towards funding a $7.4 billion settlement intended to compensate people harmed by the opioid epidemic.

Before approving the plea deal, US District Judge Madeline Cox Arleo in Newark heard nearly seven hours of testimony from people affected by the crisis. More than 200 victims submitted letters detailing personal experiences of addiction and loss, while over 40 addressed the court in person.

Judge Arleo instructed Purdue chairman Steve Miller to apologise directly to victims in court. He said the company “deeply regrets and accepts responsibility” for its past misconduct.

“We are deeply apologetic for all of the things that happened that were described in vivid detail by all the victims here today,” Miller said.

The judge also issued her own remarks, stating that the government had missed multiple opportunities to prevent Purdue from misleading doctors and patients about the addictive nature of OxyContin.

“Your government failed you,” Arleo told victims. “The inadequacy of what the law can offer today must be plainly stated.”

Several victims argued that a financial penalty was insufficient, calling instead for prison terms for executives and members of the Sackler family, who own the company, and urging the court to reject the plea deal.

“Punishment by a fine means ‘legal for a price’,” said Ed Bisch, who lost his son to an overdose in 2001.

Judge Arleo said she could not impose prison sentences on executives or owners because the US Department of Justice had not brought charges against them individually, only against the company itself.

She added that accepting the plea agreement was the most appropriate outcome available to the court, while expressing hope that future cases would ensure corporate wrongdoing was not reduced to “the cost of doing business”.

Under the agreement, most of the $5.5 billion in penalties will go unpaid, with the Justice Department set to collect $225 million provided Purdue directs remaining assets towards creditors, largely state and local governments dealing with the fallout of the opioid crisis.

The sentencing comes as victims say Purdue’s prolonged bankruptcy has left many frustrated. The broader $7.4 billion settlement, including an $865 million fund for individuals affected, has been described by the company and plaintiffs’ lawyers as a major victory for victims. However, recent reporting has highlighted significant barriers for claimants seeking compensation.

Many victims who spoke in court expressed concern that the settlement process may exclude those unable to obtain historical prescription records required to qualify for payments.

Judge Arleo urged Purdue’s legal team to adopt a more flexible approach.

“I want there to be some flexibility for victims,” she said. “We don’t simply say ‘no’ because the records are not available.”

Alexis Pleus, who lost her son after he was first prescribed OxyContin for a sports injury, said many families with similar experiences would likely not qualify for compensation.

“We still deserve justice, and this is not it,” she said.

Coming to a Close

Purdue’s bankruptcy proceedings are now nearing completion after more than six years, following multiple appeals that reached the US Supreme Court.

The sentencing marks one of the final steps before the settlement can proceed.

The company said it remains on track to exit bankruptcy on 1 May, ending its current operations and emerging as a new non-profit entity focused on opioid addiction treatment and overdose-reversal medicines.

Under the plea agreement, Purdue admitted to paying kickbacks to doctors to drive OxyContin sales and misleading federal regulators about measures to prevent illegal drug use.

The company had previously pleaded guilty in 2007 to misbranding and fraud charges relating to its marketing of OxyContin, admitting it falsely promoted the drug as less addictive and less prone to abuse than other painkillers.

 

For any enquiries or information, contact ask@tlr.ae or call us on +971 52 644 3004. Follow The Law Reporters on WhatsApp Channels.